Serum HER2 extracellular domain in metastatic breast cancer patients treated with weekly trastuzumab and paclitaxel: association with HER2 status by immunohistochemistry and fluorescence in situ hybridization and with response rate (Q57578503)
article
Language:
Current Data About Serum HER2 extracellular domain in metastatic breast cancer patients treated with weekly trastuzumab and paclitaxel: association with HER2 status by immunohistochemistry and fluorescence in situ hybridization and with response rate
(P31) (Q13442814)

(P50) (Q37644083)
(P1932) L. Norton
(P1545) 6

(P304) 234-239

(P407) (Q1860)

(P433) 2

(P478) 16

(P577) Tuesday, February 1, 2005

(P921) (Q181600)

(Q899285)
(P887)

(Q12859063)
(P887)

(Q412616)
(P887)

(Q423762)
(P887)

(P1433) (Q326122)

(P1476) "Serum HER2 extracellular domain in metastatic breast cancer patients treated with weekly trastuzumab and paclitaxel: association with HER2 status by immunohistochemistry and fluorescence in situ hybridization and with response rate" (language: en)

(P2093) M. N. Fornier
(P1545) 1

A. D. Seidman
(P1545) 2

M. K. Schwartz
(P1545) 3

F. Ghani
(P1545) 4

R. Thiel
(P1545) 5

C. Hudis
(P1545) 7

(P2860) (Q44529239)
(P248)
(P854) https://api.crossref.org/works/10.1093%2FANNONC%2FMDI059
(P813) Sunday, January 21, 2018

(P4510) (Q899285)
(P887)

other details
description article

External Links
(P356) 10.1093/ANNONC/MDI059
(P698) 15668276